Rethinking herpes simplex virus: the way to oncolytic agents (Q37882608)

24 August 2017

1 reference

title

Rethinking herpes simplex virus: the way to oncolytic agents (English)

1 reference

24 August 2017

1 reference

5

1 reference

24 August 2017

6

1 reference

Gabriella Campadelli-Fiume

24 August 2017

object named as

Gabriella Campadelli-Fiume

series ordinal

1

0 references

Carla De Giovanni

series ordinal

2

object named as

Carla De Giovanni

1 reference

24 August 2017

7

Laura Menotti

1 reference

24 August 2017

Valentina Gatta

3

1 reference

24 August 2017

Valentina Gatta

series ordinal

4

1 reference

24 August 2017

publication date

27 May 2011

1 reference

Reviews in Medical Virology

24 August 2017

published in

1 reference

24 August 2017

volume

21

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

213-226

1 reference

Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded

24 August 2017

cites work

1 reference

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

21 January 2018

1 reference

Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses

21 January 2018

1 reference

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

21 January 2018

1 reference

The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon

21 January 2018

1 reference

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

21 January 2018

1 reference

Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity

21 January 2018

1 reference

A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer

21 January 2018

1 reference

Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer

21 January 2018

1 reference

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

21 January 2018

1 reference

Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models

21 January 2018

1 reference

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

21 January 2018

1 reference

Genetically engineered HSV in the treatment of glioma: a review

21 January 2018

1 reference

Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1

21 January 2018

1 reference

Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of her

21 January 2018

1 reference

The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors

21 January 2018

1 reference

Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma

21 January 2018

1 reference

Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir

21 January 2018

1 reference

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence

21 January 2018

1 reference

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

21 January 2018

1 reference

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

21 January 2018

1 reference

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

21 January 2018

1 reference

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

21 January 2018

1 reference

Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma

21 January 2018

1 reference

Virulence of and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1.

21 January 2018

1 reference

Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver

21 January 2018

1 reference

Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver

21 January 2018

1 reference

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice

21 January 2018

1 reference

Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM

21 January 2018

1 reference

Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application

21 January 2018

1 reference

Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses

21 January 2018

1 reference

Neutralizing innate host defenses to control viral translation in HSV-1 infected cells

21 January 2018

1 reference

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

21 January 2018

1 reference

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

21 January 2018

1 reference

Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model

21 January 2018

1 reference

Oncolytic viral therapy of malignant glioma

21 January 2018

1 reference

Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung

21 January 2018

1 reference

Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

21 January 2018

1 reference

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

21 January 2018

1 reference

Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.

21 January 2018

1 reference

Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction

21 January 2018

1 reference

The multipartite system that mediates entry of herpes simplex virus into the cell

21 January 2018

1 reference

Herpes simplex virus glycoprotein D bound to the human receptor HveA

21 January 2018

1 reference

Potential nectin-1 binding site on herpes simplex virus glycoprotein d.

21 January 2018

1 reference

Mutations in herpes simplex virus glycoprotein D that prevent cell entry via nectins and alter cell tropism

21 January 2018

1 reference

Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor

21 January 2018

1 reference

Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2.

21 January 2018

1 reference

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer

21 January 2018

1 reference

Vaccines for tumour prevention

21 January 2018

1 reference

New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer

21 January 2018

1 reference

A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors

21 January 2018

1 reference

Separation of receptor-binding and profusogenic domains of glycoprotein D of herpes simplex virus 1 into distinct interacting proteins

21 January 2018

1 reference

Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells

21 January 2018

1 reference

The pro-fusion domain of herpes simplex virus glycoprotein D (gD) interacts with the gD N terminus and is displaced by soluble forms of viral receptors

21 January 2018

1 reference

Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry.

21 January 2018

1 reference

Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule

21 January 2018

1 reference

Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells.

21 January 2018

1 reference

An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor

21 January 2018

1 reference

Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses.

21 January 2018

1 reference

Enhancing radiotherapy with genetically engineered viruses

21 January 2018

1 reference

ReVOLT: radiation-enhanced viral oncolytic therapy

21 January 2018

1 reference

Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan

21 January 2018

1 reference

Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/RMV.691

1 reference

24 August 2017

1 reference